EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

ARGX

619.6

+0.42%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

ARGX

619.6

+0.42%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

ARGX

619.6

+0.42%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

ARGX

619.6

+0.42%↑

EI

289.9

-0.96%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

MRK1

135.5

-0.7%↓

ARGX

619.6

+0.42%↑

Search

Ion Beam Applications

Cerrado

13.82 -0.72

Resumen

Variación precio

24h

Actual

Mínimo

13.58

Máximo

13.88

Métricas clave

By Trading Economics

Ingresos

-10M

Ventas

206M

P/B

Media del Sector

51.704

73.394

Rentabilidad por dividendo

1.19

Margen de beneficio

-4.99

Empleados

1,943

EBITDA

-372K

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.19%

3.09%

Próximas Ganancias

20 mar 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

407M

Apertura anterior

14.54

Cierre anterior

13.82

Ion Beam Applications Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 sept 2024, 06:28 UTC

Adquisiciones, fusiones, absorciones

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Comparación entre iguales

Cambio de precio

Ion Beam Applications Esperado

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.